Tag: GlobeNewswire

Company Adds 30-Year IBM Executive and Operations Expert to Board

Fort Lauderdale, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME) – a diversified holding company and owner of Azure Holdings, a renewable power plant developer, and SemiCab Holdings, an AI-enabled logistics provider, today formally introduced its newest independent director, Greg Smith.

Mr. Smith is a highly accomplished executive in the technology industry, having spent his entire professional career with IBM. In the later years of his tenure at IBM, Mr. Smith managed multi-country organizations with direct responsibility for an annual budget of $2 billion.

Mr. Smith was recognized for his management acumen early in his career, having been promoted to an engineering management position within three years of joining IBM. Over the ensuing 30 years, Mr. Smith assumed progressively greater managerial roles within the organization, with a focus and area of expertise on business process management, and received both his PMI project management certification and IBM Project Management Executive Certification. Mr. Smith has received various IBM recognitions, including a Global Supply Chain Leadership Award. Mr. Smith received his BS in Aeronautics and a Master of Business Administration from San Jose State University.

“We are pleased to formally welcome Greg to our Board of Directors,” commented Andrew Thompson, our CEO. “Greg brings a tremendous understanding of organizational structure, as well as of creating and managing high-value client relationships. Most importantly, we expect he will help us establish a strong focus on accountability and a results-driven culture across the Algorhythm portfolio of companies.”

“In addition, Greg was a key part of the technology ecosystem that rapidly grew from the 1990s to the 2010s. He has a deep understanding of the macro forces driving the AI data center boom, and we believe his insights will be invaluable as we seek new growth opportunities to deliver power to data center infrastructure sites across the United States using our renewable biomass power plant solutions,” concluded Mr. Thompson.

About Algorhythm Holdings

Algorhythm Holdings, Inc. is a holding company with two primary assets, Azure Holdings and SemiCab Holdings. Azure Holdings, dba Azure Energy (“Azure”), is a developer of renewable biomass power generation infrastructure. Its team, including its co-founders, consists of some of the most experienced biomass power plant experts in the U.S. today. Collectively, this team has designed and built 72 facilities generating 17.5 GW of renewable power to date. Azure was launched in 2025 and has already secured equity participation, which management estimates to have a net present value of over $220 million, in multiple power plants currently under construction in the U.S. Azure has significant fee-based consulting revenues under multi-year contracts and is generating positive EBITDA. For additional information, please go to: http://www.azure-energy.co.

Algorhythm Holdings, Inc. also owns and operates SemiCab, an AI-enabled logistics software provider. Since 2020, SemiCab has enabled major retailers, brands and transportation providers to address common supply-chain problems globally. Its AI-enabled, cloud-based Collaborative Transportation Platform is designed to provide the scalability required to predict and optimize millions of loads and hundreds of thousands of trucks. SemiCab uses real-time data from API-based load tendering and pre-built integrations with TMS and ELD partners to orchestrate collaboration across manufacturers, retailers, distributors, and their carriers. SemiCab uses AI/ML predictions and advanced predictive optimization models to enable fully loaded round trips. With SemiCab’s AI platform, shippers pay less and carriers make more without having to change a thing. For additional information, please go to: http://www.semicab.com.

Investor Relations Contact

Brendan Hopkins
407-645-5295
investors@algoholdings.com
www.algoholdings.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “seeks,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. Forward-looking statements in this press release include, without limitation, statements regarding Mr. Smith’s expected contributions to the Company, the Company’s growth opportunities, including in supplying power to data center infrastructure, and the estimated value of Azure’s equity participation in power plants under construction. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in the Company’s reports to the SEC, including, without limitation, the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this press release to conform our statements to actual results or changed expectations, or as a result of new information, future events or otherwise.

SSCP Lager BidCo AB (publ) (“SSCP Lager BidCo” or the “Issuer”) today announces that the Issuer is exercising its right to make a conditional voluntary total redemption of its outstanding senior secured floating rate notes 2023/2026 with ISIN SE0021021193 (the “Notes” and the “Redemption”), in accordance with the terms and conditions of the Notes.

The redemption date of the Redemption will be 30 October 2026 (the “Redemption Date”). The Notes will be redeemed at an amount equal to 100.78125 per cent. of the nominal amount per Note (the “Redemption Price”), together with any accrued and unpaid interest. The Redemption Price, together with accrued and unpaid interest, will be paid to each person who is registered as owner of Notes in the debt register maintained by Euroclear Nordics AB at end of business on 23 October 2026 (the “Record Date”). In connection with the Redemption, the Notes will be delisted from Nasdaq Stockholm’s corporate bond list.

The Redemption is conditional upon the successful execution of a facilities agreement with, inter alios, certain lenders and the Issuer being content that the conditions for utilisation of the facilities provided in the facilities agreement will be satisfied no later than on the Redemption Date (the “Condition”). The Issuer shall not, and has no obligation to, redeem any of the Notes unless the Condition has been fulfilled or waived by the Issuer on or prior to the Record Date. The Issuer will by way of a press release inform whether or not the Condition have been met or waived or will not be satisfied.

The notice of conditional voluntary total redemption of the Notes is available on SSCP Lager BidCo’s website, via the following link: https://logentgroup.com/en/investor-relations/

For further information, please contact:

Joel Engström, CEO, telephone number: +46 734 36 36 29, joel.engstrom@logent.se

Andrzej Kulik, CFO, telephone number: +46 738 15 67 00, andrzej.kulik@logent.se

This information is information that SSCP Lager BidCo AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 6 October 2026, at 14:54 CEST.

About Logent Group
Logent is a comprehensive and independent logistics partner, with a Nordic base and with global networks. We have a wide range of services and create value for our customers through guaranteed cost and quality improvements. Our services include Logistics Services such as Warehouse Management, Transport Management and Customs, Port and Combined Terminals, Staffing Services and Consulting Services. This means that Logent has grown to a turnover of about SEK 3 billion from the start in 2006 and employs approximately 3,300 people.

Attachment

• SSCP Lager BidCo AB (publ)_06102026_en.pdf

The demonstration represents another development milestone in the Company’s development of quantum-enabled platform for high-dimensional clinical data analysis 

Tel Aviv, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) — Quantum X Labs Inc. (Nasdaq: QXL) (“Quantum X” or the “Company”), an advanced technologies company, today reported its GPU-accelerated quantum-simulation platform achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared with the same 64-vCPU machine with only CPU implementation.

The evaluation used a real clinical gene-expression dataset comprising 11 patients and 3,531 gene-expression features, representing a challenging high-dimensional setting in which the number of biological variables greatly exceeds the number of patients.

Quantum X’s proprietary algorithm, operated through its subsidiary CliniQuantum, searched for correlated three-gene configurations across the dataset. The 3,531 genes generated 7,331,162,245 possible three-gene combinations. Using a predefined minimum correlation threshold, the algorithm identified approximately 22.2 million correlated gene triplets.

The analysis required approximately 8.4 hours using 64 vCPUs, compared with approximately 0.5 hours when accelerated using a single NVIDIA T4 GPU, while producing the same qualifying gene-triplet results.

“This represents an important development milestone for Quantum X Labs,” said Dr. Tidhar Turgeman, head of clinical trials data analysis. “Clinical and molecular datasets can contain thousands of variables but relatively few patients, creating enormous combinatorial search spaces. Demonstrating the ability to evaluate more than 7.3 billion potential gene combinations on real clinical data marks an important step in our development. The significant GPU acceleration further supports our continuing development of scalable, quantum-enabled approaches for biomarker discovery and patient stratification.”

The benchmark was conducted on an AWS g4dn.16xlarge EC2 machine using IBM Qiskit Aer GPU-based quantum simulation, with an NVIDIA T4 Tensor Core GPU. The benchmark was designed to evaluate computational performance and did not evaluate or establish the clinical validity, predictive value, or potential utility of any identified gene combinations.

QuantumXLabs intends to continue advancing its algorithms toward the analysis of increasingly complex multi-feature configurations and larger biomedical datasets, while progressing its development pathway from simulation and validation toward execution on quantum computing hardware.

Quantum X Labs Inc.

Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Quantum X Labs’ and its subsidiaries’ strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the continued development and optimization of its technologies, the expansion of its research and development activities, potential applications of its solutions, the advancement of its business strategy, and its expectations regarding future performance and growth opportunities. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s most recent Annual Report on 10-K and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Quantum X Labs is not responsible for the content of third-party websites. 

Investor Relations Contacts:

Michal Efraty
Investor Relations
michal@efraty.com

Preclinical data highlighting ERNA-101’s potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center in Houston

CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that new preclinical data from its lead oncology program, ERNA-101, have been selected for a Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and The University of Texas MD Anderson Cancer Center.

The meeting will take place October 6–8, 2026, on MD Anderson’s campus in Houston, Texas. The presentation will highlight ERNA-101’s potential to address a fundamental challenge in ovarian cancer: the immunosuppressive tumor microenvironment that can limit effective antitumor immune responses. In preclinical models of high-grade serous ovarian cancer, ERNA-101 promoted immune cell recruitment and was associated with significant tumor regression and enhanced survival. When combined with PD-1 checkpoint blockade, ERNA-101 demonstrated enhanced antitumor activity, including complete tumor control and durable responses in the majority of treated animals.

“Selection for presentation at a Nature Conferences meeting co-hosted by MD Anderson Cancer Center highlights the strength of our preclinical findings for ERNA-101, and we look forward to engaging with researchers and oncology leaders focused on advancing the next generation of cancer therapies,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. “Our data demonstrate the potential of our allogeneic, off-the-shelf approach to deliver immune-activating cytokines to the tumor microenvironment, recruit key immune cells and enhance the activity of checkpoint blockade. We believe these findings provide a strong scientific foundation for advancing ERNA-101 toward the clinic and investigating its potential to address the significant unmet need in ovarian cancer.”

Presentation Details

Title: IL7-IL15-iMSCs (ERNA-101): Allogeneic, Off-the-Shelf, Next-Generation Immune-Enhancing Cell Therapy of Cancer
Session: Flash Talk Date: Tuesday, October 6, 2026
Location: The University of Texas MD Anderson Cancer Center, Houston, Texas

The presentation will feature preclinical findings demonstrating ERNA-101’s ability to recruit T cells and proinflammatory macrophages and promote an immune-active tumor microenvironment in models of high-grade serous ovarian cancer. In combination with PD-1 checkpoint blockade, ERNA-101 achieved complete tumor control and durable responses in the majority of treated animals, with the findings reproduced in a larger cohort. Biodistribution studies also showed localization of ERNA-101 to the tumor microenvironment, with no detectable signal in the peritoneal wash, serum or other organs evaluated.

Co-hosted by Nature Conferences and MD Anderson Cancer Center, the Next-Generation Cancer Therapeutics meeting will bring together researchers from academia, biotechnology and the pharmaceutical industry to discuss emerging approaches to cancer treatment, including next-generation biologics, immunotherapies, targeted therapies and novel therapeutic platforms. For more information, please visit the conference website.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About ERNA-101

ERNA-101 is Ernexa’s lead oncology program, comprising allogeneic, off-the-shelf, induced pluripotent stem cell-derived mesenchymal stromal cells (iMSCs) engineered to express IL-7 and IL-15 as a single fusion protein (IL-7_IL-15-fusokine). ERNA-101 is designed to deliver an immune-activating cytokine payload to the tumor microenvironment, promote antitumor immune responses and potentially enhance the activity of checkpoint blockade. Ernexa is advancing ERNA-101 toward clinical development for ovarian cancer.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: the Company’s ability to advance ERNA-101 toward and submit an IND application to the FDA, including the planned submission in Q4 2026; the timing, design and outcomes of the planned first-in-human clinical study of ERNA-101 in platinum-resistant ovarian cancer, including the expected availability of clinical data in Q4 2027; the Company’s ability to transition from a preclinical-stage company to a clinical-stage company; expectations regarding the versatility and therapeutic potential of the Company’s synthetic iMSC platform, including its ability to be engineered for distinct therapeutic purposes across oncology and other disease areas; the Company’s plans to broaden its oncology pipeline by evaluating additional high-need cancer indications and advancing next-generation iMSC candidates; the Company’s ability to identify, develop and advance additional product candidates; the Company’s capital allocation strategy, including the decision to pause additional preclinical development expenditures on ERNA-201 and concentrate near-term resources on ERNA-101 and oncology pipeline expansion; the potential for ERNA-201 to be advanced in the future; the Company’s ability to enter into strategic collaborations or partnerships; the sufficiency of the Company’s capital resources to fund planned operations and achieve anticipated milestones; the Company’s ability to obtain and maintain regulatory approvals for its product candidates; the Company’s ability to attract and retain qualified personnel; the Company’s ability to protect its intellectual property and proprietary technology; competition from other companies developing therapies for the same or similar indications; and general market, political and economic conditions. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date here of, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that management will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12-14, 2026, in New York, NY. The conference brings together industry leaders, innovators, and investors to explore the latest trends and advancements across several industries.

Greg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research analysts throughout the event. Dogwood recently announced the completion of enrollment in its Halneuron^® Phase 2b Trial and anticipates topline data readout of the study in November 2026.

Portions of the event will also be streamed online at https://digital.maximgrp.com/. For registration information and a complete agenda of the Maxim Growth Summit, click here.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron^® and SP16 IV.

Our lead product candidate, Halneuron^®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron^® is a non-opioid, Na_V 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain CINP. SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (“LRP1”) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

Dogwood Therapeutics’ largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing, enrollment, design and results of current and future clinical studies relating to Dogwood’s product candidates; whether interim or final clinical data will support continued development, regulatory submissions or approval; and Dogwood’s ability to finance its operations. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that management will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12-14, 2026, in New York, NY. The conference brings together industry leaders, innovators, and investors to explore the latest trends and advancements across several industries.

Greg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research analysts throughout the event. Dogwood recently announced the completion of enrollment in its Halneuron^® Phase 2b Trial and anticipates topline data readout of the study in November 2026.

Portions of the event will also be streamed online at https://digital.maximgrp.com/. For registration information and a complete agenda of the Maxim Growth Summit, click here.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron^® and SP16 IV.

Our lead product candidate, Halneuron^®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron^® is a non-opioid, Na_V 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain CINP. SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (“LRP1”) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

Dogwood Therapeutics’ largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing, enrollment, design and results of current and future clinical studies relating to Dogwood’s product candidates; whether interim or final clinical data will support continued development, regulatory submissions or approval; and Dogwood’s ability to finance its operations. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that management will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12-14, 2026, in New York, NY. The conference brings together industry leaders, innovators, and investors to explore the latest trends and advancements across several industries.

Greg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research analysts throughout the event. Dogwood recently announced the completion of enrollment in its Halneuron^® Phase 2b Trial and anticipates topline data readout of the study in November 2026.

Portions of the event will also be streamed online at https://digital.maximgrp.com/. For registration information and a complete agenda of the Maxim Growth Summit, click here.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron^® and SP16 IV.

Our lead product candidate, Halneuron^®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron^® is a non-opioid, Na_V 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain CINP. SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (“LRP1”) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

Dogwood Therapeutics’ largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing, enrollment, design and results of current and future clinical studies relating to Dogwood’s product candidates; whether interim or final clinical data will support continued development, regulatory submissions or approval; and Dogwood’s ability to finance its operations. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that management will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12-14, 2026, in New York, NY. The conference brings together industry leaders, innovators, and investors to explore the latest trends and advancements across several industries.

Greg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research analysts throughout the event. Dogwood recently announced the completion of enrollment in its Halneuron^® Phase 2b Trial and anticipates topline data readout of the study in November 2026.

Portions of the event will also be streamed online at https://digital.maximgrp.com/. For registration information and a complete agenda of the Maxim Growth Summit, click here.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron^® and SP16 IV.

Our lead product candidate, Halneuron^®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron^® is a non-opioid, Na_V 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain CINP. SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (“LRP1”) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

Dogwood Therapeutics’ largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing, enrollment, design and results of current and future clinical studies relating to Dogwood’s product candidates; whether interim or final clinical data will support continued development, regulatory submissions or approval; and Dogwood’s ability to finance its operations. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that management will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12-14, 2026, in New York, NY. The conference brings together industry leaders, innovators, and investors to explore the latest trends and advancements across several industries.

Greg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research analysts throughout the event. Dogwood recently announced the completion of enrollment in its Halneuron^® Phase 2b Trial and anticipates topline data readout of the study in November 2026.

Portions of the event will also be streamed online at https://digital.maximgrp.com/. For registration information and a complete agenda of the Maxim Growth Summit, click here.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron^® and SP16 IV.

Our lead product candidate, Halneuron^®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron^® is a non-opioid, Na_V 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain CINP. SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (“LRP1”) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

Dogwood Therapeutics’ largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing, enrollment, design and results of current and future clinical studies relating to Dogwood’s product candidates; whether interim or final clinical data will support continued development, regulatory submissions or approval; and Dogwood’s ability to finance its operations. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

ATHENS, Greece, Oct. 06, 2026 (GLOBE NEWSWIRE) — Rubico Inc. (Nasdaq: RUBI) (the “Company” or “Rubico”), a global provider of shipping transportation services specializing in the ownership of vessels, announced today the closing of the previously announced share purchase agreement dated July 27, 2026 with Top Ships Inc., a related party, pursuant to which the Company acquired the shares of a company (the “SPV”) that is party to a shipbuilding contract with Guangzhou Shipyard International Company Limited for the construction of a 47,499 dwt chemical/product oil carrier (the “Newbuilding MR Tanker”). The Newbuilding MR Tanker is scheduled for delivery in the second quarter of 2029. The SPV has secured time charter employment for the vessel with a major oil trader, starting from its delivery and for a firm duration of seven years, with charterer’s option to extend for four additional years.

Kalliopi Ornithopoulou, the Company’s President, Chairwoman & Chief Executive Officer, stated:

“Following this closing of our third modern newbuilding MR tanker, our total potential gross revenue backlog, including available charterer extension optional years, from our three newbuilding MR tankers, is approximately $226.3 million. Including contracted time charters for our operating fleet and assuming the exercise of all available charter extension options, our total potential gross revenue backlog amounts to approximately $374.6 million, providing significant revenue visibility for future periods. This strategy of acquiring modern newbuilding tankers, with 85% of their shipbuilding installments financed, supports our fleet growth objectives while increasing contracted revenue visibility over the long term.

In addition, we have completed our previously announced stock dividend of 0.50 common shares for each common share outstanding, with our shares trading ex-dividend as of today. We believe these initiatives further enhance Rubico’s position as the owner of a modern, fuel-efficient tanker fleet.”

About the Company

Rubico Inc. is a global provider of shipping transportation services specializing in the ownership of vessels. The Company is an international owner and operator of two modern, fuel efficient, eco 157,000 dwt Suezmax tankers. Furthermore, the Company owns three 47,499 dwt MR tanker newbuildings scheduled for delivery in the second, third and fourth quarters of 2029 and a 60-meter newbuilding megayacht scheduled for delivery in the second quarter of 2027, which the Company intends to divest.

The Company is incorporated under the laws of the Republic of the Marshall Islands and has executive offices in Athens, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “RUBI”.

Please visit the Company’s website at: https://rubicoinc.com/

For further information please contact:

Nikolaos Papastratis
Chief Financial Officer
Rubico Inc.
Tel: +30 210 812 8107
Email: npapastratis@rubicoinc.com

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts, including statements regarding the construction, delivery, employment and financing of the Company’s newbuilding vessels, including the financing of 85% of their shipbuilding installments, potential gross revenue backlog, the declaration of optional periods under the related time charters and the potential divestiture of the Company’s newbuilding megayacht.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections. Please see the Company’s filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.